

BEIKE BIOTECHNOLOGY

A Descriptive Statistical Report on 38 Ataxia Cases with Cell Therapy From 2007, 2008, and 2009

Background

This descriptive report covers subjective information collected by questionnaires from our overseas ataxia patients confirmed before the hospital-admission. Participating patients were treated in 2007, 2008, and 2009. This information mainly includes the efficacy assessment of the cell therapy on four time points: immediately after the treatment, one month, three months and six months after the treatment. The data for this analysis is based solely on patients from 2007-2009 who submitted the questionnaire to our followup department.

Results

Diagnosis: Patients were asked to provide their ataxia diagnosis and the breakdown is as follows: 2 patients with SCA1, 2 with SCA2, 7 with SCA3, 2 with SCA6, 6 with Friedreich's, and 18 with unspecific forms. This breakdown can be viewed on Chart 1 of the next page.

General Effectiveness: General effectiveness was measured by a Yes/No question asked to the patient and/or patient's caregiver. The question asked if the patient had any improvement at any time after the treatment. The general effectiveness percentage is 68.4% (26/38 patients). The analysis results by diagnosis are as follows (first number is number improved, second number is total amount with the diagnosis): SCA1 - 2/2, SCA2 - 3/3, SCA3 - 6/7, SCA6 - 1/2, and Friedreich's - 3/6.

Improvement Immediately After the Treatment: The effectiveness rate at the time point immediately after the treatment for total improved patients is 23 out the 26 patients (88.4%).

Improvement at 1 Month, 3 Months, and 6 Months: There were 2 patients at one month and 1 patient at three months after the treatment that received their first improvements at these time points. A representation of these numbers can be seen on page two in Chart 2. No patients received their first improvements at 6 months after treatment.

Conclusions

For the 38 patients, the general effectiveness percentage is 68.4% (percent of total patients that received improvement). 23 of these patients received improvements immediately after treatment, while only 3 patients received their first improvements at least one month after the treatment. 12 patients did not receive any improvements within one year after the treatment. It is statistically important that only 3 patients received first improvements at least 1 month after discharge. This followup demonstrates that only a small minority of patients will see their first improvements after discharge from the hospital.

Chart 1: Forms of Ataxia





Chart 2: When Patients First Noticed Improvement (After Treatment)



Disclaimer: The information contained in this document is to be used solely as a reference for observing patients' subjective opinions and observations about treatment efficacy.

BEIKE BIOTECHNOLOGY CO., LTD.

International Office

Flat 601, Unit 2, Bldg 4, Da Gong Hai An
48 Dong Hai Xi Road
Qingdao, China 266071

Head Office

9th Floor, Zhongke Building, 1 South Street
South Area, Shenzhen Hi-Tech Industrial Park
Shenzhen, China 518057